8-K current report · filed Aug 13, 2026

PTC THERAPEUTICS, INC. (PTCT) 8-K Current Report: August 13, 2026

Item 8.01Item EX-99.1Item 7.01PTCT overview

Short answer

PTC THERAPEUTICS, INC. (PTCT) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). PTC selected as winning bidder to acquire ST-920 from Sangamo in a competitive Chapter 11 bankruptcy auction.

PTC THERAPEUTICS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • PTC selected as winning bidder to acquire ST-920 from Sangamo in a competitive Chapter 11 bankruptcy auction
  • ST-920: BLA-stage, one-time AAV gene therapy candidate for Fabry disease
  • Potential pipeline expansion into Fabry disease through an advanced gene therapy asset
  • Acquisition terms and financial obligations detailed in Exhibit 99.1 press release

Item 8.01 · Other Events

  • Planned ST-920 acquisition: $111 million upfront plus up to $100 million FDA approval milestones
  • Milestones include $80 million for accelerated approval and $20 million for traditional or full approval
  • Closing targeted for late Q3 or early Q4 2026, pending bankruptcy court approval, antitrust review, and customary conditions
  • Rolling FDA BLA submission expected in Q4 2026, supported by 52-week Phase 1/2 STAAR data
  • International regulatory approval pursuit expands potential ST-920 commercialization scope

Item EX-99.1 · Exhibit EX-99.1

  • Winning bid to acquire ST-920, a BLA-stage Fabry gene therapy, for $111 million upfront and up to $100 million milestones
  • Acquisition expected to close late Q3 or early Q4 2026, pending bankruptcy court approval, antitrust review and definitive documentation
  • Rolling FDA BLA submission targeted for completion in Q4 2026, with potential U.S. commercial launch in 2027
  • Phase 1/2 data showed positive mean annualized eGFR slope at Week 52 and sustained enzyme activity up to 4.5 years
  • Transaction leverages PTC’s existing rare-disease infrastructure while management expects no impact on cash-flow break-even target in 2026

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other PTC THERAPEUTICS, INC. 8-K filings

Get the next PTCT 8-K as it lands

Follow PTCT for push alerts, or ask the research agent what this filing means.